In an editorial, Matthew Milowsky, MD, FASCO, wrote that the promise of incorporating new treatments and predictive biomarkers to select the right patient for the right treatment every time offers a bright future for bladder cancer patients.
UNC Lineberger is the first cancer center to enroll participants in a national study focused on expanding access to cervical cancer screening through self-testing, an approach that could help reduce the number of women diagnosed with cervical cancer due to underscreening.
Jonathan Serody, MD, and Jen Jen Yeh, MD, were named the 2023 recipients of the Hyman L. Battle Distinguished Cancer Research Award, recognizing their significant scientific achievements.
Joshua Zeidner, MD, a hematologist/oncologist specializing in the management of acute leukemia, explains some of the advances in the treatment of acute myeloid leukemia (AML).
Naim Rashid, PhD, has received a Department of Defense Pancreatic Cancer Research Program pilot award to build an AI tool that generates personalized clinical trial recommendations for patients with PDAC.
UNC Lineberger members were part of an international research consortium focused on reducing health risks associated with radiation therapy for childhood cancers.
William Kim, MD, and Tracy Rose, MD, MPH, published a review highlighting new scientific insights that have led to advances in kidney cancer treatment and increased survival rates.
UNC and UNC Lineberger researchers and trainees will be presenting talks and participating in scientific and educational panels and discussions on the latest cancer research at the ASCO Annual Meeting.
In a commentary in JAMA Oncology, José Gaston Guillem, MD, MPH, MBA, FACS, FASCRS, cautions against the rush to extend the treatment approach to patients whose cancer has nearly, but not completely, responded to chemotherapy and radiation therapy.